Novo's oral GLP-1 meets Phase II endpoint

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) gained $2.38 to $47.55 in New York and DKK13.10 to DKK310.4 in Copenhagen on Friday after it said oral semaglutide ( OG217SC) met the primary endpoint of a 600-patient Phase II trial to treat Type II diabetes.

Novo said doses of the oral long-acting glucagon-like peptide-1 (GLP-1) analog ranging from 2.5 mg to 40 mg improved HbA1c levels by 0.7-1.9% at 26 weeks, all statistically significant improvements over 0.3% for patients receiving placebo, the trial's primary endpoint. 1 mg subcutaneous semaglutide improved HbA1c by 1.9%. ...